Newsbenzinga
Bristol-Myers Boosts 2026 Guidance on Portfolio Strength
· Published
Article summary
Bristol-Myers beats Q2 earnings and revenue estimates, driven by growth drugs, while raising its full-year 2026 sales and profit outlook.
An excerpt from the original article.
Comments —
Loading comments…